A Pilot Study of Pembrolizumab Immunotherapy for Previously Treated High-Grade Neuroendocrine Cancers

Full Title

CC #169524: A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Purpose

The purpose of this study is to assess the use of pembrolizumab immunotherapy in patients with aggressive neuroendocrine cancers that continue to grow despite prior treatment. Earlier studies have indicated that this treatment is effective against neuroendocrine lung cancers; doctors believe that pembrolizumab may also be active against neuroendocrine tumors in other parts of the body.

Pembrolizumab blocks PD-1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an inoperable or metastatic high-grade neuroendocrine tumor outside the lungs.
  • Patients’ cancers must have continued to grow despite previous treatment.
  • Patients should recover from the serious side effects of previous treatments before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Nitya Raj at 646-888-4849.

Protocol

18-004

Phase

Pilot

Investigator

Co-Investigators